Compare LAES & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | TTRX |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 298.8M |
| IPO Year | 2022 | 2025 |
| Metric | LAES | TTRX |
|---|---|---|
| Price | $1.47 | $10.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.88 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 3.6M | 84.5K |
| Earning Date | 09-11-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $59.43 | N/A |
| Revenue Next Year | $41.92 | $900.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $2.57 |
| 52 Week High | $7.26 | $16.45 |
| Indicator | LAES | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.30 | 40.90 |
| Support Level | N/A | $9.29 |
| Resistance Level | $2.56 | $10.72 |
| Average True Range (ATR) | 0.11 | 0.81 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 7.76 | 19.47 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.